Skip to main content
. 2018 Feb 26;170(1):35–43. doi: 10.1007/s10549-018-4730-1

Table 1.

Clinicopathological features of the study cohort (n = 1010)

Parameters Number (%)
Age (year)
 < 40 133 (13.2)
 ≥ 40 877 (86.8)
Menopause
 Yes 399 (39.5)
 No 611 (60.5)
Chemotherapy cycles
 3 29 (2.9)
 4 900 (89.2)
 5–8 81 (7.9)
Subtypes of cancer
 Ductal 986 (97.6)
 Lobular 13 (1.3)
 Others 11 (1.1)
Tumor size
 < 2 cm 74 (7.3)
 2–4 cm 522 (51.7)
 ≥ 4 cm 414 (41.0)
Clinical nodal status
 Positive 473 (46.8)
 Negative 537 (53.2)
Histological grade
 I 26 (2.6)
 II 578 (57.3)
 III 130 (12.9)
 Unknown 276 (27.2)
Response evaluation
 pCR 131 (13.0)
 cPR 574 (56.8)
 cSD 290 (28.7)
 cPD 15 (1.5)
 Responder (pCR and cPR) 705 (69.8)
 Non-responder (cSD and cPD) 305 (30.2)

pCR pathological complete response, cPR clinical partial response, cPD clinical progressive disease, cSD clinical stable